MARKET

IMUX

IMUX

Immunic Inc
NASDAQ
13.05
+0.75
+6.10%
After Hours: 13.07 +0.02 +0.15% 19:43 05/22 EDT
OPEN
12.50
PREV CLOSE
12.30
HIGH
13.80
LOW
12.48
VOLUME
327.03K
TURNOVER
--
52 WEEK HIGH
15.10
52 WEEK LOW
5.06
MARKET CAP
177.76M
P/E (TTM)
-2.4065
1D
5D
1M
3M
1Y
5Y
1D
Immunic Is Maintained at Buy by B. Riley Securities
Dow Jones · 1d ago
Immunic Price Target Cut to $27.00/Share From $40.00 by B. Riley Securities
Dow Jones · 1d ago
B. Riley Securities Maintains Buy on Immunic, Lowers Price Target to $27
Benzinga · 1d ago
B. Riley cuts Immunic target, sees ‘compelling entry point’
TipRanks · 1d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Cardiff Oncology (CRDF), ACADIA Pharmaceuticals (ACAD) and Immunic (IMUX)
TipRanks · 1d ago
Immunic director Michael W. Bonney files initial beneficial ownership statement
PUBT · 4d ago
Immunic appoints Michael Bonney as chair
TipRanks · 5d ago
Immunic Appoints Michael W. Bonney As Board Chairman
Benzinga · 5d ago
More
About IMUX
Immunic, Inc. is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is engaged in pursuing clinical development of programs, which include the vidofludimus calcium (IMU-838) program, which is in Phase III clinical development for patients with relapsing multiple sclerosis (RMS), and which has shown therapeutic activity in Phase II clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis; the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, Graft-versus-Host-Disease and weight management, and the IMU-381 program, which is a molecule being developed to specifically address the needs of gastrointestinal diseases.

Webull offers Immunic Inc stock information, including NASDAQ: IMUX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMUX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMUX stock methods without spending real money on the virtual paper trading platform.